Current evidence and clinical relevance of drug-microbiota interactions in inflammatory bowel disease

Current evidence and clinical relevance of drug-microbiota interactions in inflammatory bowel disease

BackgroundInflammatory bowel disease (IBD) is a chronic relapsing-remitting disease. An adverse immune reaction toward the intestinal microbiota is involved in the pathophysiology and microbial perturbations are associated with IBD in general and with flares specifically. Although medical drugs are...

Full description

Bibliographic Details
Main Authors: Heike E. F. Becker, Karlijn Demers, Luc J. J. Derijks, Daisy M. A. E. Jonkers, John Penders
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-02-01
Series:Frontiers in Microbiology
Subjects:
inflammatory bowel disease
Crohn’s disease
ulcerative colitis
microbiome
pharmacomicrobiomics
drug treatment
Online Access:https://www.frontiersin.org/articles/10.3389/fmicb.2023.1107976/full

Internet

https://www.frontiersin.org/articles/10.3389/fmicb.2023.1107976/full

Similar Items